Lung cancer: district active treatment rates affect survival
- PMID: 12011196
- PMCID: PMC1732161
- DOI: 10.1136/jech.56.6.424
Lung cancer: district active treatment rates affect survival
Abstract
Study objective: This study investigates variation in management and treatment of lung cancer patients and determines the impact of any variation in treatment on survival.
Design: A retrospective study of population based data held by the Northern & Yorkshire Cancer Registry and Information Service (NYCRIS), comparing active treatment rates for lung cancer with survival by districts. SETTING The then 17 districts in Yorkshire and South Humber, England.
Patients: 22 654 patients registered with lung cancer between 1986 and 1994 and followed up until end of 1996.
Results: The overall rates of active treatment (surgery, radiotherapy, and chemotherapy) varied between districts from 37% to 56%. One year survival (with 95% CI) was significantly better in the districts with highest rates of active treatment 23% (22% to 24%) compared with 19% (17% to 20%) for those with lowest treatment rates. Non-small cell lung cancer patients (55%) in the districts with highest active treatment rates had an age adjusted relative risk of death during the follow up period, relative to risk of death in the districts with the lower treatment rates of 0.88 (0.83 to 0.92). Clinically diagnosed patients (34%) had an age adjusted RR of 0.92 (0.86 to 0.96). RR in small cell cancer (11%) was not significant.
Conclusion: This study has shown wide variations in the rates of active treatment for lung cancer patients within districts across one large region of England. Active treatment was strongly associated with improved survival, especially in non-small cell lung cancer.
Similar articles
-
Variation in survival of patients with lung cancer in Europe, 1985-1989. EUROCARE Working Group.Eur J Cancer. 1998 Dec;34(14 Spec No):2191-6. doi: 10.1016/s0959-8049(98)00312-8. Eur J Cancer. 1998. PMID: 10070286
-
Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Arch Phys Med Rehabil. 2008. PMID: 18373987 Review.
-
Age and the treatment of lung cancer.Thorax. 1996 Jun;51(6):564-8. doi: 10.1136/thx.51.6.564. Thorax. 1996. PMID: 8693434 Free PMC article.
-
Lung cancer survival in Northern Ireland.Ir Med J. 2003 Sep;96(8):237-40. Ir Med J. 2003. PMID: 14653375
-
[Evaluation of survival and prognostic factors of 2,000 broncho-pulmonary cancers registered during 10 years in a multidisciplinary oncology department].Bull Cancer. 1997 Feb;84(2):155-61. Bull Cancer. 1997. PMID: 9180838 Review. French.
Cited by
-
Survival from lung cancer in England and Wales up to 2001.Br J Cancer. 2008 Sep 23;99 Suppl 1(Suppl 1):S43-6. doi: 10.1038/sj.bjc.6604584. Br J Cancer. 2008. PMID: 18813257 Free PMC article. No abstract available.
-
An alternative approach to quantifying and addressing inequity in healthcare provision: access to surgery for lung cancer in the east of England.J Epidemiol Community Health. 2004 Jul;58(7):623-5. doi: 10.1136/jech.2003.013391. J Epidemiol Community Health. 2004. PMID: 15194729 Free PMC article.
-
Inequalities in non-small cell lung cancer treatment and mortality.J Epidemiol Community Health. 2015 Oct;69(10):985-92. doi: 10.1136/jech-2014-205309. Epub 2015 Jun 5. J Epidemiol Community Health. 2015. PMID: 26047831 Free PMC article.
-
Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis.PLoS Med. 2013;10(2):e1001376. doi: 10.1371/journal.pmed.1001376. Epub 2013 Feb 5. PLoS Med. 2013. PMID: 23393428 Free PMC article.
-
Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival.Thorax. 2006 Mar;61(3):232-9. doi: 10.1136/thx.2005.040477. Epub 2005 Nov 11. Thorax. 2006. PMID: 16284219 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical